Ticker LaunchUplisting · PCSA
Processa Pharmaceuticals, Inc.
Formerly Heatwurx, Inc.
Processa Pharmaceuticals, Inc. (PCSA), already reporting to the SEC, moved up to Nasdaq Capital Market on Oct 5, 2020 with an offering at $4.00 per share raising $19.2M. Craig-Hallum was lead-left underwriter, joined by Benchmark. Foley & Lardner advised the company and Faegre Drinker advised the underwriters.
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing drugs for patients with high unmet medical needs. Its most advanced candidate, PCS499, is an oral tablet that has completed the patient portion of a Phase 2A trial, and it has also licensed four other drugs.
- Status
- Uplisting
- Ticker
- PCSA
- Exchange
- Nasdaq Capital Market
- Listed
- Oct 5, 2020
- Price
- $4.00
- Raised
- $19.2M
- Market cap at IPO price
- $41.3M
- First filed
- Nov 14, 2012
- Underwriters
- Craig-Hallum and Benchmark
- Company counsel
- Foley & Lardner
- Underwriters' counsel
- Faegre Drinker
- Sector
- Biotech & pharma
- Country / state
- FL
More on this listing for subscribers
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Nov 14, 2012
- Latest amendment Sep 30, 2020
- Final prospectus (424B4) Oct 5, 2020
- All filings on EDGAR CIK 1533743
Other Biotech & pharma uplistings in 2020
- Cyclo Therapeutics, Inc.CTDH · Dec 11, 2020 · $12.5M
- Nomad Power Solutions, Inc.LIXT · Nov 27, 2020
- GeoVax Labs, Inc.GOVX · Sep 28, 2020 · $12.8M
- Biovie Inc.BIVI · Sep 18, 2020 · $15.7M
- Panbela Therapeutics, Inc.SNBP · Aug 31, 2020
- Windtree Therapeutics Inc /de/WINTD · May 21, 2020 · $20M